Gut Dysbiosis as a Central Driver of HS — The Mechanism Explained

Why the Gut Matters in a Skin Condition

The first response many patients have when told that gut health is relevant to their HS is understandable scepticism. They are experiencing painful lesions on the skin — in the underarm, the groin, beneath the breast. The gut seems distant, unrelated, almost a distraction from the actual problem. This reaction is understandable. It reflects a view of the body as a collection of systems that operate largely in parallel, with the skin being a self-contained organ whose problems are primarily skin-derived.

The gut-skin axis does not work that way. The gut is not simply a digestive organ. It is the body's primary interface with the external environment — the site at which food, microorganisms, and inflammatory compounds are either successfully processed and contained, or allowed to pass into the broader systemic circulation. When gut function is compromised, it does not produce only gut symptoms. It generates a systemic inflammatory state that expresses itself wherever the body has a pre-existing susceptibility — and in HS patients, that susceptibility is concentrated in the follicular tissue of specific anatomical regions.

Understanding why the gut is relevant to HS requires understanding three things: what goes wrong in gut dysfunction, how that dysfunction translates into systemic inflammation, and why that inflammation specifically amplifies what is happening in HS-affected tissue.

What Gut Dysfunction Actually Means

Gut dysfunction in the context of HS is not primarily about symptoms like bloating, constipation, or diarrhoea — though these may coexist. It refers to a specific combination of structural and functional failures in the intestinal environment that collectively generate a chronic, low-grade systemic inflammatory signal.

The intestinal barrier is the first issue. The intestinal lining, when functioning well, is selectively permeable — it allows digested nutrients to pass into the bloodstream while keeping incompletely metabolised compounds, bacterial components, and inflammatory molecules contained within the gut. When the barrier is compromised — through poor diet, antibiotic exposure, chronic stress, or sustained inflammation — this selectivity breaks down. Compounds that should remain in the gut enter systemic circulation, where the immune system registers them as threats and mounts an inflammatory response. This response is not acute and dramatic. It is chronic and sustained — a persistent low-level activation that keeps inflammatory markers elevated and the immune system in a state of ongoing readiness.

Microbial dysbiosis — an imbalance in the composition of the gut microbiome — compounds this problem. A healthy microbiome performs regulatory functions that go well beyond digestion: it modulates immune responses, produces compounds that maintain the integrity of the intestinal lining, and actively suppresses certain inflammatory pathways. When the microbial balance shifts — toward a state where less diverse, more inflammatory bacterial populations predominate — these regulatory functions are impaired. The gut becomes less capable of containing its own inflammatory load, and the systemic inflammatory burden increases.

Digestive insufficiency is a third layer. When food is incompletely broken down — whether due to insufficient digestive enzyme activity, poor bile acid function, or inadequate stomach acid — the resulting incompletely processed compounds become substrates for bacterial fermentation and inflammatory processes within the gut. This generates additional toxic metabolites that enter circulation and add to the systemic inflammatory load. It is a less immediately visible failure than barrier dysfunction, but it contributes meaningfully to the overall inflammatory picture.

How Gut Dysfunction Translates to HS Activity

The translation from gut dysfunction to HS activity occurs through the systemic inflammatory state that gut dysfunction generates and sustains. This state does not directly cause follicular occlusion or trigger the immune response that drives HS lesions — but it creates and maintains the internal environment in which those events occur more readily, resolve more slowly, and produce more extensive tissue damage when they do occur.

Consider what happens when a hair follicle becomes blocked. In a person without significant systemic inflammation, this is typically a minor event — the blockage may resolve spontaneously, the immune response is proportionate, and even if a small inflamed lesion forms, it resolves completely and leaves minimal structural consequence. In a person carrying a significant systemic inflammatory burden from gut dysfunction, the same follicular blockage triggers a response that is characteristically disproportionate. The sustained systemic inflammation has primed the immune system to respond to even minor tissue events as significant threats. The result is the deep, painful, destructive inflammatory lesion characteristic of HS — not because the follicular event itself was more severe, but because the internal context in which it occurred was fundamentally different.

The Antibiotic Paradox

This understanding makes visible a significant paradox in conventional HS management: the primary pharmaceutical intervention — repeated antibiotic courses — directly worsens one of the primary drivers of the disease. Antibiotics reduce the bacterial component of active HS lesions, producing temporary improvement. But they also disrupt the gut microbiome, reducing its diversity, impairing its regulatory functions, and worsening the intestinal barrier integrity that prevents systemic spread of inflammatory compounds.

Each antibiotic course provides short-term relief at the cost of a further degradation of gut function — which worsens the systemic inflammatory baseline — which makes the next HS episode more likely to occur, more severe when it does, and more likely to require another antibiotic course. Many patients who have been managed with repeated antibiotic courses for years find that their HS has progressively worsened over that period. The antibiotic treatment is not the sole reason for that progression — but it is a contributing factor that is rarely acknowledged in the treatment rationale offered to patients.

The Gut-Hormone Connection in HS

The gut's role in HS extends beyond the direct generation of systemic inflammation. The gut also participates meaningfully in hormonal regulation — and hormonal imbalance, particularly androgen excess, is a second major driver of HS in a significant proportion of patients, especially women.

The gut microbiome contains a community of bacteria — sometimes referred to as the estrobolome — that produce enzymes involved in the metabolism and reactivation of hormones, including oestrogens. Dysbiosis alters the activity of these bacterial populations in ways that impair hormonal clearance, allowing hormones that should be deactivated and excreted to re-enter circulation. This contributes to hormonal dysregulation not through the endocrine system directly, but through the gut's failure to adequately process and eliminate hormones as part of normal metabolic clearance.

Insulin resistance — a central metabolic driver in many HS patients — is also bidirectionally linked to gut health. Gut dysbiosis worsens insulin sensitivity through several mechanisms, including altered short-chain fatty acid production and increased systemic inflammation. Insulin resistance in turn worsens hormonal imbalance, particularly by increasing androgen availability. The gut is not just one driver among many in HS — it sits at a junction point where its dysfunction simultaneously amplifies the inflammatory burden and impairs the hormonal regulatory environment that HS also depends on to sustain itself.

Recognising Gut Contribution in an HS Patient

Gut dysfunction does not always announce itself through obvious digestive symptoms. Many HS patients with significant gut-mediated inflammatory contribution report unremarkable digestive function — no chronic bloating, no alternating bowel patterns, no diagnosed inflammatory bowel condition. The gut can be generating a meaningful systemic inflammatory burden while producing symptoms that are subtle or absent. This makes it easy to dismiss as a factor — and easy to overlook in an evaluation focused primarily on the skin.

A structured assessment looks beyond symptomatic gut function to consider: dietary patterns and their likely effect on microbiome diversity; history of antibiotic use and its cumulative impact on gut ecology; signs of systemic inflammation that are consistent with gut-mediated origin; and the relationship between dietary changes and HS flare activity — a relationship many patients have observed empirically, even if they have not understood its mechanism. These observations, taken together, often reveal a gut contribution that was not visible from the skin presentation alone.

What Gut Restoration Requires

Restoring gut function in the context of HS is not achieved through a single dietary change or a probiotic supplement. It is a structured process that addresses the multiple layers of gut dysfunction that typically coexist in patients with chronic HS.

The first requirement is reducing the inflammatory inputs that are sustaining the gut dysfunction — dietary patterns that feed inflammatory bacterial populations, foods that directly compromise intestinal barrier function, and lifestyle factors that impair the gut's regenerative capacity. This is not a generic exclusion diet. It is a personalised reduction of the specific inputs most relevant to the individual's pattern of gut dysfunction.

The second requirement is active support for intestinal barrier restoration. The compromised barrier does not repair itself automatically when inflammatory inputs are reduced — it requires specific support for the cellular regeneration of the intestinal lining, restoration of the mucus layer that forms the barrier's first line of defence, and re-establishment of the tight junction integrity that determines selective permeability.

The third requirement is microbiome restoration — not through generic probiotic supplementation, but through a combination of dietary and formulation-based approaches that selectively support the growth of regulatory bacterial populations and reduce the dominance of inflammatory ones. This is a slower process than barrier repair, and it requires sustained intervention over a period that reflects the time it takes for microbial communities to genuinely re-establish.

The Practical Significance

For patients who have managed HS for years with skin-directed interventions — and experienced the predictable cycle of temporary improvement followed by relapse — understanding the gut's role as a central driver reframes what treatment must accomplish. The question is not merely how to clear the current lesion. It is how to alter the internal environment that is producing lesions. And in a significant proportion of HS cases, that environment is being sustained, at its foundation, by a gut that is generating more inflammatory load than it is resolving.

Addressing this is not straightforward. It requires a structured assessment of gut function, a personalised approach to dietary and formulation-based correction, and sufficient time for restoration to occur. But it is the intervention that reaches the origin of the inflammatory signal — rather than simply managing its expression. And reaching the origin is what changes the trajectory of the disease, rather than its current episode.